The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
@ConsDoms
I am not saying you are not right about the timeline when concluding the IND has been submitted to the FDA on Monday 8-5-2023, as this was not a bank holiday in the U.S.
But I'll argue that POTENTIALLY, just potentially the IND could already have been submitted Friday the 5-5-2023, after closing of the stock exchange here in London, but while everything is still in full swing on the east coast.
And we would still not have been informed about the IND application having been submitted any earlier then Tuesday the 9-5-2023 at 0700.
IF, that should happen to be the case, then the 30 days will end Sunday the 4-6-2023.
And again if that is the case, then we will wake up to a nice RNS on Monday the 5-6-2023
Against this theory goes the assumption that the FDA do not like to receive an application on a Friday.
Does Rio Tinto need Greatland Gold?
NO.
No is my simple answer to that question. They do not need Greatland Gold.
Nor do they need to sell up to 75% of a promising asset for peanuts.
Although, I doubt we will ever get to own more than 51% of the new company.
But that is still an incredible giveaway at an incredibly low price by Rio Tinto.
Don't get me wrong, it is nice that for once it is Greatland Gold that is doing a fantastic deal for peanuts.
But there must be a master plan behind this.
My take is that Rio Tinto would like to get in on the action in some of the other tenements that Greatland Gold owns.
And giving some of their own tenements up could be the price for consideration.
I most definitely see it as goodwill and am looking forward to working with them in the future.
@dhub at 10:23
I think you are onto something when you say: "That says it all really"
I bought a few shares today, and for that to happen there has to have been a seller.
So whoever that was: THANK YOU
I am pretty sure it was not dhub selling, although he was checking if it was possible to sell 6 million shares.
But of course, I cannot rule the possibility out completely, as it would demand information that I do not have.
What I can say with complete conviction, is that if dhub had in fact put 6 million shares up for sale, then the Market Maker would not have bought them of him, to fill my order.
So, there must be a big order out there, or several less big orders out there.
And if that is the case, then the share price staying at this level is nothing but games being played at this point.
@Cyrox
Isn't it a bit to early for that:-)
But they are most definitely somewhere else then here, so your suggestion is as good as any.
In fact I'll say it's the SHINIEST example I've seen today:-)
@Blastoid7
Thanks for reminding me about Sareum, I have not dealt with them for quite a while now.
As your pointing out, no traction despite a lot of action on the clinical front.
And that is the bit that worries me. It seems like the market has ZERO appetite for risky pharma stocks at the moment.
And if that is the case, then we will not see a rerate until the market believe we will get a cash flow.
But boy do I wish I am wrong about that and that JustHereForHemo is right and there will be a substantial rerate over the next 3 weeks.
But if that does not happen just like that, then the 3 main catalysts I see are:
FDA accelerate the approval of HEMO Car-T in the next couple of days.
(Yes, I know the difference is merely a few weeks, but the sign of approval should give the market confidence)
The market likes the partner Hemogenyx announces in the roll out of HEMO Car-T.
Patients has been signed up and clinical trials are about to commence.
With everything going for HEMOGENYX at the moment, and the news of the IND application out there, it beats me that there is no more traction in this share.
Where are all the risk takers, where are all the traders?
Where are all the investors that like a cheap company right on the cusp of significant changes?
@Hemotruth
The answer to your question is very simple.
There is not enough new investors with enough appetite to increase the share price.
Supply and demand in it's purest form.
Maybe it will increase a bit as we get closer to the 30th day after which we are likely to be clinical.
But as things stands at the moment, I do not expect the rerate we are all dreaming about until we are a clinical company.
And again, because it is as it is at the moment, I am questioning if the rerate will happen at that point, maybe it will first happen later when clinical trials start, or maybe even first later then that, when the first Patient is cured.
And if the rerate has not happened by then, then I might start to entertain various conspiracy theories:-)
@HedgeHogarth
I'd like to chime on here as well that I will miss your posts here.
And I'll urge you to reconsider setting up a forum on your own, as I am sure there could be unforseen legal liabilities that you'll have to contend with.
So better to just take a break from here and hopefully we'll see you here again soon.
But at that time, try not to engage with posters that comes across as potentially having ulterior motives of some sort.
Either way, thanks for many a great posts and all the best for the future.
Okay, so I had another go at finding out about the patent.
Have a look at this document:
https://wp-nanosynth-2021.s3.eu-west-2.amazonaws.com/media/2022/06/1._Nanosynth_Group_financial_statement_28.06_-ZAK-updated.pdf
Look at page 37, where they talk about the value of the intellectual property.
Or see page 31 where it states:
"Intellectual Property is amortised at 20% per annum on a straight-line basis. "
But maybe most importantly page 41 where it states:
"At acquisition Pharm 2 Farm Limited had rights over intellectual property under 15 year licences signed in 2019. "
To me that sounds like there is 11 years left on a licence.
A licence which could potentially be sold.
The question is if there is a buyer and not least if we as shareholders could be secured the right to a first dip?
@unitedguy
Thanks for the information Unitedguy.
Is it possible that you can post a link showing that Nottingham Trent University is the owner of the patent and that there is nothing that can be bought from the left over of NNN that can be of value in this regard.
I have just had a quick look but have not found anything.
It's my hope that you can save me a lot of time if you know exactly where to look.
Regarding taking class action, count me out.
Either things have rightfully gone wrong and there is nothing to address or if it is a deliberate act, then it is likely to have been covered up so well, that it will be hard to prove, as a wall of denial can be difficult to penetrate and not least prove.
Thanks in advance
I am shocked by today's announcement.
I had not seen it coming based on the RNS's released that talked about all the opportunities ahead of us.
And especially not after going to the AGM and talking to one of the members of BOD.
Yes, choppy waters ahead, but I expected nothing less from an AIM company in this development state.
But I did not expect this.
The only way I see we can salvage some value here is if club together and buy the Intellectual property.
I assume it is to be auctioned off.
Let's make that clear at the upcoming meeting that we think it is preferable that we as shareholders get the first dip on the intellectual property.
I think concerned shareholders should contact "ReSolve Advisory Limited" and ask about the possibility that we can acquire the intellectual property and what the price would be available.
@Mumbo_Jumbo
It could be as little as a fortnight.
But in reality, it is probably going to be longer.
They first have to get Patients and doctors who are willing to participate in the Phase I experiment.
Maybe they already have them lined up, but if they don't, then it will take the time it will take.
I believe with the connections that HEMOGENYX got they have already lined up doctors that are interested in giving this Phase I drug a go.
Then it is just a question if there are any Patients that are willing to take the risk.
Take a chance on HEMOGENYX (Sorry, couldn't resist getting an ABBA inspired quote in:-)
Because it is a risk.
It's a risk of time.
Their time.
Will this unknown experimental drug buy them more precious time with their loved ones?
Will this unknown experimental drug give them more comfort and fewer side effects?
Is this experimental drug from HEMOGENYX likely to be better than any other experimental drug or treatment that might be available?
If there are any risks worth contemplating and talking about at the moment, then these are the ones in my view.
I have made my bet, I have placed my money where my mouth is, and if I am right, then there are going to be a lot of winners.
Not least the Patient's lives who are going to be saved.
@HedgeHogarth
Although I take that it is a couple of years ago that your wife passed away, I would like to pass on my condolences, you know better late then never.
I appreciate the time you put into correcting the misinformation that some individuals post on here, what ever their motivation might be.
Personally I am afraid that it is more sinister then your suggestions, as I cannot fathom why any one would spend the time and effort on this share with a small turnover being traded daily and just a small % change.
@mryummy
I am afraid you are getting ahead of yourself.
Around the 2 pence mark per share the company would have a market cap around 100 million.
To justify that, it would have to be one hell of a gold find.
I am not saying, that won't be the case, but equally, I cannot say that it will be the case either, so I would advise caution hunting pies in the sky, although it is tempting with the current low share price and the number of shares £1000 can get you.
But don't forget there are more than 4.5 BILLION shares in circulation in this company.
I think there is money to be made here, but I very much doubt the share price will reach 20 pence per share without some sort of consolidation.
@JustHereForHemo
Your arguments do indeed show why it is so important that HEMO ensures just enough is said about CBR to keep the fire burning, but not so much that a competitor can easily decipher and overcome the obstacles and create a competing product.
And also why it is so important that Hemo spends all the possible time they have at its disposal on researching its invention and covering as many possible outcomes as it can possibly think of to ensure that other companies can only deal in this field in the next 20 years if they buy a licence from HEMOGENYX.
Now wouldn’t that be something?
And that is just one of the reasons, why I would not be in favour of a buyout.
At any price.
Yes, even £10 a share.
Admittedly, I get ahead of myself here, but I stand by it.
I honestly believe that if CBR can deliver what we hope and dream it can without severe side effects, then a market cap of 11 Billion is a joke.
Again admitted, it will take years and many trials to get to that stage, but I have patience, especially as I do not believe for a second, the share price would stay down here in the single pence region if and when we get the news we all want and so desire on CBR.
But first things first.
Hemo Car-T, is ready to get rolled out. There is just that little matter of IND to be sorted first and it is likely that it will be sorted in a matter of days or a few weeks at the most as it has been applied for.
If this product is effective (Hurray for Patients) then maybe it can be either cash generative before the end of 2024 or sold for a significant sum, which will allow the development of CBR.
Either case is desirable for me.
Especially keeping the product, ourselves and building a name in the medical field and consumers' mind.
We should hopefully be able to borrow money against our income or projected income.
I am not of the opinion that getting for instance 100 million here and now for HEMO Car-T is the best option, CBR can be proven to be safe and work for the income from HEMO Car-T.
It will take years, but it would take years anyway, even with 100 million in the bank account.
But I must admit that having 100 million in a bank account would undoubtedly have a positive effect on the share price.
But no matter what, if CBR works, if we want the maximum financial outcome, we do not get that as shareholders by selling the company to one of the big boys.
Collaboration YES.
Selling NO.
@catcatbar
I agree with the sentiment that no news is good news when it comes to CBR, insofar as to understand that had it utterly and completely failed with no hope of resurrection then it would have to be RNS'ed.
That is not to say that it therefor must have been plain sailing in the lab, they may have encountered issues, but if they have then they cannot have been of a magnetude that demands an RNS.
Personally, I hope everything has been progressing at a decent speed and accordingly to expectations while HEMO was focusing on HEMO Car-T.
Giving extra time in research is not a bad thing in my book, it improves the chances to discover either added benefits or unwished side effects.
But when it comes to your hopes of HEMO bringing an event forward time wise, I would not get my hopes up.
If history is anything to go by, it's not a bet that I would take.
But I am sure you can entrust them to comply with the rules, whatever they may be, so they do not loose their rights to CBR.
@dhub
5 pence when we have the all clear to start with clinical trials, sounds a bit conservative to me, if not downright pessimistic:-)
But what do I know, and should I be totally surprised bearing in mind the way this share has acted in the past 6 month or so?
Becoming clinical (especially if fast track), news on partner, news on CBR are all awaited and should be a catalyst.
But again, we are quite a few who have known so for a long time, and it has not happened yet.
"But mark you my words, one day, one day it will happen"
My thread from yesterday gathered a lot of traction, so much so that the original post drowned.
Therefore I've decided to repost it as the news is still out there and that might be worthwhile for any potential new investors looking in over the weekend to be aware of.
I tried to google: Hemogenyx IND application
And I got some of the following results:
https://www.bloomberg.com/press-releases/2023-05-09/hemogenyx-pharmaceuticals-plc-announces-submission-of-ind-for-hemo-car-t
https://www.asktraders.com/analysis/hemogenyx-shares-edged-7-92-higher-on-the-fda-ind-application/
https://www.morningstar.co.uk/uk/news/AN_1683641789718054200/in-brief-hemogenyx-submits-fda-application-for-hemo-car-t-treatment.aspx
https://twitter.com/HemogenyxPharma/status/1329204764853366784
https://shareprices.com/news/in-brief-hemogenyx-submits-fda-application-for-hemo-car-t-treatment-l4y1xy26j9eqefs/
https://www.accesswire.com/753708/Hemogenyx-Pharmaceuticals-PLC-Announces-Submission-of-IND-for-HEMO-CAR-T
https://www.linkedin.com/posts/vladislavsandler_westandwithukraine-activity-6904425722543493120-uuqF
https://cbonds.com/news/2301946/
https://www.marketscreener.com/quote/stock/HEMOGENYX-PHARMACEUTICALS-24857735/news/Hemogenyx-submits-FDA-application-for-Hemo-Car-T-treatment-43790564/
https://www.voxmarkets.co.uk/listings/LON/HEMO/
And last but not least, we got LSE (save the best for last:-)
https://www.lse.co.uk/rns/HEMO/submission-of-ind-for-hemo-car-t-bvkk4erik7cropt.html
In other words, the news about Hemogenyx’s IND application is out there.
So, why the lacklustre rise in the share price?
I still think we need a different kind of investor here. Someone with a different mindset.
I do not expect to see the significant gains that we are all hoping for until it is announced that we are clinical (which could happen as early as next week)
But hey, small 5-10% gains on a daily basis up until then would not be bad either:-)
The news is out there.
I tried to google: Hemogenyx IND application
And I got some of the following results:
https://www.bloomberg.com/press-releases/2023-05-09/hemogenyx-pharmaceuticals-plc-announces-submission-of-ind-for-hemo-car-t
https://www.asktraders.com/analysis/hemogenyx-shares-edged-7-92-higher-on-the-fda-ind-application/
https://www.morningstar.co.uk/uk/news/AN_1683641789718054200/in-brief-hemogenyx-submits-fda-application-for-hemo-car-t-treatment.aspx
https://twitter.com/HemogenyxPharma/status/1329204764853366784
https://shareprices.com/news/in-brief-hemogenyx-submits-fda-application-for-hemo-car-t-treatment-l4y1xy26j9eqefs/
https://www.accesswire.com/753708/Hemogenyx-Pharmaceuticals-PLC-Announces-Submission-of-IND-for-HEMO-CAR-T
https://www.linkedin.com/posts/vladislavsandler_westandwithukraine-activity-6904425722543493120-uuqF
https://cbonds.com/news/2301946/
https://www.marketscreener.com/quote/stock/HEMOGENYX-PHARMACEUTICALS-24857735/news/Hemogenyx-submits-FDA-application-for-Hemo-Car-T-treatment-43790564/
https://www.voxmarkets.co.uk/listings/LON/HEMO/
And last but not least, we got LSE (save the best for last:-)
https://www.lse.co.uk/rns/HEMO/submission-of-ind-for-hemo-car-t-bvkk4erik7cropt.html
In other words, the news about Hemogenyx’s IND application is out there.
So, why the lacklustre rise in the share price?
I still think we need a different kind of investor here. Someone with a different mindset.
I do not expect to see the significant gains that we are all hoping for until it is announced that we are clinical (which could happen as early as next week)
But hey, small 5-10% gains on a daily basis up until then would not be bad either:-)
@Chris0123
I agree with so much of what you're saying.
However, I wonder if it wouldn't give a higher price jump if the following was to happen:
1. Announcement of a significant partner
2. IND approved after 30 days.
3. And even better IND is approved after 10 days only.
4. Fantastic news on CBR.
I think this combination would be a bigger winner, simply because HEMO will than already have shown that they can deliver, are clinical and have the ability to attract a significant partner.
If that does not give the market confidence, then I do not know what it takes.
It has now gone past 0800 and the trading day has started.
But what will it bring?
We now know IND has been submitted and it is going to be interesting to see how many have been waiting on the side lines for this specific moment.
How many are they and what is their purchase capability is.
The last bit is particularly important as that is the driver of the share price.
But another important thing is if they are "JUST" traders or long-term investors as I suspect that will have an effect on sustaining the new share price level.
3 or 4 pence represent a 50 to 100% increase. Many traders would happily sell for less and this could cause a yo-yo effect until we become clinical in less than 30 days or so (and of course we become clinical)
But, I guess that is fair enough, trading this stock has pretty much been the only way to make money in this share in recent years.
However, I do not doubt that we have turned a significant corner. And the era for Long term investors has just kicked off.
Whether you wish to make your money by trading this share or as a long-term shareholder, today the start pistol was fired and I wish you the best of luck.
But let us not forget, hopefully soon there will be a cure for AML and HEMOGENYX will start to save patients' life.